Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Passes Below 200-Day Moving Average - What's Next?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $12.62 and traded as low as $10.31. Enanta Pharmaceuticals shares last traded at $10.43, with a volume of 115,856 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ENTA shares. JMP Securities reiterated a "market outperform" rating and set a $22.00 price objective on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 9th. Evercore ISI raised Enanta Pharmaceuticals to a "strong-buy" rating in a report on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. Finally, JPMorgan Chase & Co. dropped their price objective on Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating for the company in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Enanta Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $20.00.

Enanta Pharmaceuticals Price Performance

The firm has a market capitalization of $214.65 million, a PE ratio of -1.91 and a beta of 0.56. The business has a 50-day simple moving average of $11.43 and a 200-day simple moving average of $12.60.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company's stock worth $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company's stock worth $588,000 after purchasing an additional 18,003 shares in the last quarter. American Century Companies Inc. grew its stake in Enanta Pharmaceuticals by 35.4% in the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock worth $362,000 after purchasing an additional 7,287 shares in the last quarter. Rhumbline Advisers grew its stake in Enanta Pharmaceuticals by 4.7% in the second quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company's stock worth $448,000 after purchasing an additional 1,548 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company's stock worth $958,000 after purchasing an additional 8,645 shares in the last quarter. Institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.